Organic compounds

$3.19 Billion CPVC Pipe & Fitting Market by Type, Application, Geographic Scope - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on:

Wednesday, July 21, 2021

Construction & Property, Other Construction & Property, Organic polymers, Plastics, Plumbing, Piping, Organic compounds, Building materials, Chlorinated polyvinyl chloride, Pipe, Plastic pipework, Polyvinyl chloride, High-density polyethylene

The "CPVC Pipe & Fitting Market by Type, by Application, by Geographic Scope And Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points:

Global CPVC Pipes and Fittings Market was valued at USD 1,407.8 Million in 2020 and is projected to reach USD 3,019.9 Million by 2027, growing at a CAGR of 11.52% from 2020 to 2027.
The global construction industry is growing at a rapid pace for the past few years.
The rising applications of CPVC pipe in new infrastructure owing to its excellent mechanical and chemical properties can offer a lucrative growth opportunity for CPVC pipe & fitting in the construction industry.
Moreover, a rising number of water treatment plants worldwide is are expected to augment the growth of the CPVC pipe & fitting market over the forecast period.

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Retrieved on:

Tuesday, July 20, 2021

Organic compounds, Chemical compounds, Quinazolines, Tyrosine kinase receptors, Amines, Astellas Pharma, Erlotinib, Ethers, Epidermal growth factor receptor, Chemistry

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.

Key Points:

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.
Both product candidates are exclusively licensed forU.S.commercialization withGalderma Holding SA.
The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
For additional information, please visit www.sol-gel.com .

Dystrophin (DMD) Drugs In Development, 2021 Research Report - ResearchAndMarkets.com

Retrieved on:

Tuesday, July 20, 2021

Health, Pharmaceutical, Muscular dystrophy, Branches of biology, Dystrophin, DMD, Chemical compounds, Organic compounds, Ezutromid, Drisapersen

The "Dystrophin (DMD) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Dystrophin (DMD) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
Dystrophin (DMD) - Dystrophin is a cytoplasmic protein.
The report 'Dystrophin - Drugs In Development, 2021' outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects.

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis

Retrieved on:

Monday, July 19, 2021

Chemical compounds, Organic compounds, Amides, Ethers, Morpholines, Pyridines, Tirbanibulin, Chemistry, Actinic keratosis, Almirall, AK

This approval by the European Commission marks another significant milestone for Klisyri, shortly following the marketing approval and launch of Klisyri in the U.S., said Dr. Johnson Lau, Chief Executive Officer of Athenex.

Key Points:

This approval by the European Commission marks another significant milestone for Klisyri, shortly following the marketing approval and launch of Klisyri in the U.S., said Dr. Johnson Lau, Chief Executive Officer of Athenex.
In December 2020, Athenex received approval from the U.S. Food and Drug Administration (FDA) for the commercialization of Klisyri (tirbanibulin) in the U.S. for the topical treatment of AK of the face or scalp.
Our partner Almirall led the U.S. launch of Klisyri in February and is leading the launch of Klisyri in Europe.
Klisyri (tirbanibulin) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) of the face or scalp.

G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer

Retrieved on:

Monday, July 19, 2021

Organic compounds, Chemical compounds, G1 Therapeutics, Chemistry, Breakthrough therapy, Trilaciclib, G1

Fast Track designation underscores the urgent need for innovative drugs that can significantly improve TNBC patient outcomes, said Raj Malik, M.D., Chief Medical Officer at G1 Therapeutics.

Key Points:

Fast Track designation underscores the urgent need for innovative drugs that can significantly improve TNBC patient outcomes, said Raj Malik, M.D., Chief Medical Officer at G1 Therapeutics.
It provides an important pathway to help expedite the development and regulatory review of COSELA in this indication.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .
G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

Retrieved on:

Saturday, July 17, 2021

Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.

Key Points:

Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.
A corresponding trial in Europe, CARISEL, is examining the implementation of long-acting cabotegravir and rilpivirine, dosed every 2-months in certain European healthcare settings.
Marketing Authorisations for the long-acting regimen of cabotegravir and rilpivirine were granted by the European Medicines Agency in December 2020.
Sustainment of implementation strategies was assessed via surveys and semi-structured interviews of staff study participants as well as patient study participants.

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

Retrieved on:

Saturday, July 17, 2021

AIDS, Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Medical specialties, Hepatotoxins, Prevention of HIV/AIDS, HIV/AIDS, Management of HIV/AIDS, Zidovudine, HIV, Lenacapavir, Discovery and development of HIV-protease inhibitors, HIV vaccine development

If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.

Key Points:

If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.
Lenacapavir is a potentially first-in-class capsid inhibitor without overlapping resistance with any currently approved antiretroviral therapy (ART).
Lenacapavir is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.
Data presented at AIDS 2020 from a Phase 1 study support further evaluation of lenacapavir administered subcutaneously every six months for both HIV-1 treatment and prevention.

FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

Retrieved on:

Thursday, July 15, 2021

Enzymes, Chemical compounds, Acetic acids, Organic compounds, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Anemias, Myelodysplastic syndrome, HIF prolyl-hydroxylase inhibitor, Procollagen-proline dioxygenase, Chronic kidney disease

Roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first HIF-PH inhibitor accepted by the FDA for review for the treatment of anemia of CKD.

Key Points:

Roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first HIF-PH inhibitor accepted by the FDA for review for the treatment of anemia of CKD.
Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).
The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia of chronic kidney disease (CKD).
Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc.

Retrieved on:

Thursday, July 15, 2021

Software, Organic compounds, Chemical compounds, NCCN, Neratinib, Twitter, Instagram

Proposals were peer reviewed by a Scientific Review Committee, which consisted of leading expert medical oncologists from NCCN Member Institutions.

Key Points:

Proposals were peer reviewed by a Scientific Review Committee, which consisted of leading expert medical oncologists from NCCN Member Institutions.
Puma is providing $1.4 million in funding and will also supply the neratinib tablets for use in the studies.
In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database .
Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg , Instagram @NCCNorg , and Twitter @NCCN .

Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)

Retrieved on:

Wednesday, July 14, 2021

Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Atypical antipsychotics, Piperidines, Pimavanserin, Ureas, Acadia Pharmaceuticals, Chemistry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimers Association International Conference 2021 (AAIC), being held July 26-30, 2021 in Denver, Colo., and virtually.

Key Points:

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimers Association International Conference 2021 (AAIC), being held July 26-30, 2021 in Denver, Colo., and virtually.
The poster presentations include two analyses of patients who have neurodegenerative disease taking pimavanserin while also receiving other antidementia medication.
In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors.
Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components.